Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

BACKGROUND: Preclinical studies suggest that combining vandetanib (VAN), a multi-tyrosine kinase inhibitor of rearranged during transfection (RET) proto-oncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR), with everolimus (EV), a mammalian targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cascone, T., Sacks, R.L., Subbiah, I.M., Drobnitzky, N., Piha-Paul, S.A., Hong, D.S., Hess, K.R., Amini, B., Bhatt, T., Fu, S., Naing, A., Janku, F., Karp, D., Falchook, G.S., Conley, A.P., Sherman, S.I., Meric-Bernstam, F., Ryan, A.J., Heymach, J.V., Subbiah, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973128/
https://www.ncbi.nlm.nih.gov/pubmed/33721621
http://dx.doi.org/10.1016/j.esmoop.2021.100079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973128/
https://www.ncbi.nlm.nih.gov/pubmed/33721621
http://dx.doi.org/10.1016/j.esmoop.2021.100079

Ejemplares similares